Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3006337 in overweight/obesity with hepatic steatosis
NCT05970640Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YH25724 in non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Drug-related Adverse Events up to 99 days. Started Aug 2023; status: completed.
02
Drugs
YH25724
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05970640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970640.